- Home
- FOF vs IVVD Comparison
FOF vs IVVD Comparison
Compare FOF & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- IVVD
- Stock Information
- Founded
- FOF 2006
- IVVD 2020
- Country
- FOF United States
- IVVD United States
- Employees
- FOF N/A
- IVVD N/A
- Industry
- FOF Investment Managers
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- IVVD Health Care
- Exchange
- FOF Nasdaq
- IVVD Nasdaq
- Market Cap
- FOF 362.3M
- IVVD 351.6M
- IPO Year
- FOF N/A
- IVVD 2021
- Fundamental
- Price
- FOF $13.03
- IVVD $1.61
- Analyst Decision
- FOF
- IVVD Strong Buy
- Analyst Count
- FOF 0
- IVVD 5
- Target Price
- FOF N/A
- IVVD $6.11
- AVG Volume (30 Days)
- FOF 58.7K
- IVVD 6.2M
- Earning Date
- FOF 01-01-0001
- IVVD 11-07-2025
- Dividend Yield
- FOF 9.07%
- IVVD N/A
- EPS Growth
- FOF N/A
- IVVD N/A
- EPS
- FOF N/A
- IVVD N/A
- Revenue
- FOF N/A
- IVVD $46,210,000.00
- Revenue This Year
- FOF N/A
- IVVD $102.11
- Revenue Next Year
- FOF N/A
- IVVD $151.51
- P/E Ratio
- FOF N/A
- IVVD N/A
- Revenue Growth
- FOF N/A
- IVVD 1941.08
- 52 Week Low
- FOF $9.59
- IVVD $0.35
- 52 Week High
- FOF $11.75
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- FOF 50.07
- IVVD 46.79
- Support Level
- FOF $12.86
- IVVD $1.74
- Resistance Level
- FOF $13.16
- IVVD $2.00
- Average True Range (ATR)
- FOF 0.14
- IVVD 0.24
- MACD
- FOF -0.00
- IVVD -0.06
- Stochastic Oscillator
- FOF 47.29
- IVVD 1.33
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.